EU/3/20/2278

About

On 4 June 2020, orphan designation EU/3/20/2278 was granted by the European Commission to Clinical Network Services (NL) B.V., Netherlands, for rilzabrutinib (also known as PRN1008) for the treatment of immune thrombocytopenia.

In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.

Key facts

Active substance
Rilzabrutinib
Disease / condition
Treatment of immune thrombocytopenia
Date of first decision
04/06/2020
Outcome
Positive
EU designation number
EU/3/20/2278

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Scendea (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: orphan@scendea.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating